SCHEMBL4855385

SCHEMBL4855385

COC(=O)c1ccc(Cl)cc1Nc1ccc(CO)cc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.56
MAPT P10636 4/20 0.45
ALDH1A1 P00352 4/20 0.45
HPGD P15428 4/20 0.45
GAA P10253 3/20 0.45
KDM4E B2RXH2 2/20 0.45
HSD17B10 Q99714 2/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
LMNA P02545 1/20 0.42
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
CA3 P07451 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4852723 0.89 ABL1 (0.52) ABL1MAPTALDH1A1HPGDGAA
SCHEMBL4855150 0.87 ABL1 (0.50) ABL1MAPTALDH1A1HPGDGAA
SCHEMBL4854787 0.87 MEN1 (0.47) ALDH1A1GAAKDM4EHSD17B10TSHR
SCHEMBL4854740 0.86 ABL1 (0.60) ABL1MAPTALDH1A1HPGDGAA
SCHEMBL1290704 0.85 KDM4E (0.60) ABL1MAPTALDH1A1HPGDGAA
SCHEMBL4855887 0.84 ABL1 (0.57) ABL1MAPTALDH1A1HPGDGAA
SCHEMBL4857888 0.83 CHKA (0.46) ABL1MAPTALDH1A1HPGDGAA
SCHEMBL4856783 0.82 HCRTR1 (0.53) ABL1MAPTALDH1A1HPGDGAA
SCHEMBL4853821 0.82 ABL1 (0.61) ABL1MAPTALDH1A1HPGDGAA
SCHEMBL4856548 0.81 TDP1 (0.46) ABL1MAPTALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 EP disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed
CN-1780821-A Heterocyclic kinase inhibitors. ABBOTT LAB (US) 2006-05-31 CN disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 ABL1 45/4885MAPT 4057/4885ALDH1A1 2391/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 ABL1 32/4885MAPT 3753/4885ALDH1A1 3257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.